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A b stra c t
The Gc<q pathway is essential for animal life and is a central pathway for driving locomotion, egg 
laying, and growth in Caenorhabditis elegans, where it exerts its effects through EGL-8 
(phospholipase Cp [PLCP]) and at least one other effector. To find the missing effector, we 
performed forward genetic screens to suppress the slow growth and hyperactive behaviors of mutants 
with an overactive Gaq pathway. Four suppressor mutations disrupted the Rho-specific 
guanine-nucleotide exchange factor (GEF) domain of UNC-73 (Trio). The mutations produce defects 
in neuronal function, but not neuronal development, that cause sluggish locomotion similar to animals 
lacking EGL-8 (PLCp). Strains containing null mutations in both EGL-8 (PLCP) and UNC-73 (Trio 
RhoGEF) have strong synthetic phenotypes that phenocopy the arrested growth and near-complete 
paralysis of Gaq-null mutants. Using cell-based and biochemical assays, we show that activated C. 
elegans Gaq synergizes with Trio RhoGEF to activate RhoA. Activated Gaq and Trio RhoGEF 
appear to be part of a signaling complex, because they coimmunoprecipitate when expressed together 
in cells. Our results show that Trio’s Rho-specific GEF domain is a major Gctq effector that, together 
with PLCp, mediates the Gctq signaling that drives the locomotion, egg laying, and growth of the 
animal.
[Keywords: G aq, Trio, Rho, phospholipase C(), C. e le g a n s]
The Gctq pathway is one of the major routes through which receptor-generated signals affect the state 
and function of neurons and other cells (Hubbard and Ilepler 2006). Like other members of the 
family of heterotrimeric G proteins, Gctq becomes activated when a ligand, such as a neurotransmitter, 
binds to a Gaq-coupled receptor. This causes the receptor to act as a guanine-nucleotide exchange 
factor (GEF) that converts Gctq from its inactive GDP-bound state into its active GTP-bound state and
facilitates its dissociation from the Py subunits of the G protein (Gilman 1987; Hepler and Gi.li.man 
1992; Neer 1995; Bourne 1997).
In their activated state, the Got and Py subunits activate specific effector proteins that ultimately 
change the state of the cell. Thus, to understand how a G protein pathway affects a cell’s functional 
state, it is crucial to identify all of the effector proteins through which the G protein acts. Early 
pioneering studies of the Ga.q pathway revealed that phospholipase Cp (PLCP) is an important Gotq 
effector protein (Smrcka et al. 1991; Taylor et al. 1991). Gaq-activated PLCp cleaves the lipid PIP2 
into the small signaling molecules DAG and IP3. More recently, there has been an emerging body of 
evidence definitively linking Gaq-coupled receptors and activated Gotq to Rlio activation, independent 
of effects on PLCp (Katoh et al. 1998; Chikumi et al. 2002; Putt et al. 2002; Vogt et al. 2003; Barnes 
et al. 2005; Lutz et al. 2005, 2007; Rojas et al. 2007). However, the biological significance of this 
newly discovered Gaq effector pathway has not been determined, thus leaving fundamental questions 
unanswered. For example, what is the relative importance of each effector pathway in the total 
scheme of Gaq signaling? Are both pathways active in the same cells at the same time, or are they 
specialized for different cell types or responses? Given the key role of Gaq signaling in many 
different cell types (Wilkie et al. 1991; Hubbard and Hepler 2006) and that it is essential for animal 
life (Brundage et al. 1996; Offemianns et al. 1998), these are important questions to answer.
Since the Gotti pathway is highly conserved in all animals (-82% identical between Caenorhabditis 
elegans and humans), genetic studies in model organisms provide a way to address the above 
questions. In C. elegans neurons, a synaptic signaling network of heterotrimeric G protein pathways, 
including a core Gaq pathway, controls synaptic activity to produce behaviors such as locomotion and 
egg laying (see Fig. 1 and references in legend). Under standard C. elegans culture conditions, 
animals lacking a Gaq pathway exhibit a larval growth arrest and strong paralysis that can be acutely 
rescued to wild-type levels of locomotion by applying phorbol esters, which are DAG analogs 
(Brundage et al. 1996; Reynolds et al. 2005). Gaq reduction-of-function mutants survive to become 
sluggish or paralyzed egg-laying-defective adults with impaired neurotransmitter release (Brundage el 
al. 1996; Miller et al. 1996, 1999; Hajdu-Crouin et al. 1999; Lackneretal. 1999).
Figure 1.
The missing G aq effector pathway and targeted  forward genetic sc ree n s  for finding it.
(A) Sum m ary of the G a0 and G aq pathw ays that drive C. e le g a n s  locomotion and egg 
laying. Solid lines indicate that direct interactions are  known (more ...)
Past genetic studies have shown that the C. elegans Gaq ortholog, known as EGL-30 for its 
egg-laying-defective phenotype, exerts its effects in part through EGL-8, which is the only neuronal 
PLCp ortholog in C. elegans (Lackneretal. 1999; Miller et al. 1999; Bastiani et al. 2003). However, 
these studies all inferred at least one other Gaq effector pathway based on the finding that a Gaq-null 
mutant is much more impaired for locomotion, egg laying, and growth than a mutant lacking EGL-8 
(PLCP) (Lackncr et al. 1999; Miller et al. 1999; Bastiani et al. 2003). In this study, we used two 
forward genetic screen strategies to identify candidates for the missing Gotq effector. In so doing, we 
recovered mutations that disrupt the Rho-specific GEF domain of UNC-73 (Trio). Through 
complementary genetic, biochemical, and cell-based approaches, we show that Trio’s Rho-specific 
GEF domain is a major Gaq effector that, together with PLCp, mediates the Gaq signaling that drives 
the locomotion, egg laying, and growth of the animal. These results provide the first insights into the 
relative importance of the RhoGEF and PLCP Gciq effector pathways in the context of a living
animal.
R e su lts
Loss-of-funotion mutations in Trio’s Rho-specific G EF domain suppress 
mutants with a hyperactivated Gaq pathway
To identify the missing Gaq effector pathway in C. elegans, we first performed a forward genetic 
screen to look for mutations that enhanced the phenotypes of egl-8  (PLCP)-null mutants to the point 
that they resembled Gdq-null mutants. Specifically, we looked for mutations that conferred wild-type 
or sluggish phenotypes in a wild-type background but showed strong paralysis and/or larval arrest in 
an egl-8-mA\ background (see Materials and Methods). We carried out the screen clonally and, over 
13 weekly cycles, examined enough animals to test every gene in the C. elegans genome an average 
of approximately three times for a role in the missing Gaq effector pathway. However, we found no 
clear enhancer mutations in the screen. Although this screen was too small to ensure recovery of 
domain-specific mutations or reduction-of-fiinction mutations in genes with lethal null phenotypes, it 
revealed that strong synthetic interactions with egl-8  (PLCP)-null mutants are rare, and that a simple 
gene knockout is probably insufficient to reveal the missing Gaq effector.
To continue searching for the missing Gaq effector pathway, we designed forward genetic screens in 
which we attempted to suppress or partially suppress mutants with an overactive Gaq pathway, with 
the rationale that mutations in downstream effectors would block or partially block the effects of an 
overactive Gaq pathway. To carry out these screens, we mutagenized go a- / (Ga0)-null mutants as 
well as egl-30  (Gaq) gain-of-function mutants (Fig. IB). As depicted in Figure ! A, previous genetic 
studies showed that GOA-1 (Ga0) exerts its inhibitory effects in a Gc/q-pathway-dependent manner, 
so goa-1 -null mutants effectively have an overactive Gaq pathway (Hajdu-Cronin et al. 1999; Miller 
et al. 1999). Both goa-7-null and egl-30  gain-of-function mutants have very slow growth and 
hyperactive behaviors. Our genetic screens sought to suppress both of these phenotypes. This allowed 
us to select against nonspecific mutations, such as mutations that slow locomotion (e.g., by disrupting 
muscle function) without improving growth rate, and to select for mutants with a growth advantage.
After screening ENU-mutagenized lines at an estimated fivefold to 15-fold knockout coverage for the 
combined screens, we recovered mutants satisfying the suppression criteria and mapped the mutations 
to specific genes. Among other genes, we recovered mutations in expected targets such as egl-30  
(Gaq), egl-8  (PLCP), and ric-8  (GEF for Gaq). These mutations and others will be described 
elsewhere. Unexpectedly, however, both of the genetic screens produced mutations with strong 
suppression phenotypes in the previously identified unc-73 gene (Fig. 2A-C). For example, the ce362  
mutation improved the growth rate of the goa-1 null more than sixfold, to a level that was 83% of the 
unc-73(ce362) single mutant (Fig. 2B). The strongest suppressor mutant from each of the screens also 
suppressed the locomotion rate of goa-./-null and egl-30  gain-of-function mutants to a level that was 
similar to the sluggish locomotion rate of each unc-73 single mutant (Fig. 2C).
Mutations in un c-73  (Trio) su p p ress the growth and locomotion phenotypes of 
m utants with a  hyperactivated G aq pathway. (A) The u n c-73 (ce362)  mutation c au ses  
a  striking change in the ap p ea ran ce  of a  g oa-1  (G a0)-null m utant. The photographs 
(m ore ...)
Figure 2.
UNC-73 is the C. elegans Trio ortholog (Steven et al. 1998). Its functions are mediated largely by 
two prominent GEF domains that activate small monomeric G proteins by catalyzing the transition 
from the inactive GDP-bound state to the active GTP-bound state. UNC-73’s first GEF domain is 
specific for Rac GTPases (Steven et al. 1998) and the second for Rho GTPases (Tig. 3; Spencer et al. 
2001). With alternative transcripts, C. elegans can make proteins that have the Rho-specific GEF 
domain but lack the Rac-specific GEF domain (Fig. 3; Steven et al. 2005). All four of our unc-73 
mutations specifically disrupt the Rho-specific GEF domain with missense mutations or a 
two-amino-acid deletion (Fig. 3; Supplementary Fig. 1). A previous study produced the ev802 
deletion that eliminates this domain and showed that it causes larval arrest and sluggish locomotion 
(Steven et al. 2005). Like unc-73(ev802), our mutations confer sluggish locomotion (Fig. 3), which 
suggests that they are loss-of-function mutations; however, even our strongest suppressor mutant, 
unc-73(ce362), did not exhibit larval arrest, and none of our mutants had a locomotion rate as low as 
the ev802 deletion mutant (Fig. 3), so all four suppressor mutations are likely to be 
reduction-of-function mutations but not nulls. Our molecular analysis of the mutations also suggests 
that at least two of the four mutations, ox3J7 and ce362, reduce the RhoGEF function of the domain 
and are not unusual activating mutations. ox3l 7 is likely to reduce function because it is analogous to 
a residue in Trio’s Rac-specific GEF domain that, when mutated, nearly eliminates Rac nucleotide 
exchange activity (Liu et al. 1998). Interestingly, our ce362 mutant and the ev802 deletion mutant 
both have significantly stronger locomotion and growth phenotypes than ox317, suggesting that 
ox317 does not completely knock out GEF activity in vivo. As described below, the ce362 mutation 
strongly reduces the function of the domain, or its ability to be activated, in cell-based and 
biochemical assays. Hereafter, we refer to mutants that specifically disrupt the UNC-73 Rho-specific 
GEF domain as unc-73 RhoGEF mutants.
Figure 3.
Four m utations that su p p ress m utants with an overactive G aq pathway disrupt 
UNC-73’s Rho-specific GEF domain. Shown a re  sca le  drawings com paring the 
domain structures of hum an Trio, hum an p63RhoG EF, and the eight alternative gene  
products (more ...)
The sluggishness of unc-73 RhoGEF mutants is caused by defects in 
neuronal function, not neuronal development
All of the unc-73 mutations that were previously isolated in forward genetic screens disrupt the 
animal’s ability to make a functional Rac-specific GEF domain, which is found only in unc-73’s 
longer A and B transcripts; however, animals carrying mutations upstream of the short transcripts 
C-F can still make a functional Rho-specific GEF domain (Fig. 3; Steven et al. 2005). Mutations 
disrupting the A and B transcripts cause animals to be uncoordinated because of developmental
defects in cell migrations, including axonal growth cone migrations (Hedgecocket al. 1987; Desai et 
al. 1988; Siddiqui 1990; Siddiqui and Culotti 1991; Mclntire et al. 1992; Wightman et al. 1997; 
Steven et al. 1998). Given UNC-73’s prominent role in neuronal development, we wanted to test if 
defects in neuronal development contribute to the sluggishness of unc-73 RhoGEF mutants. To do 
this, we expressed the unc-73e cDNA under control of an inducible heat-shock promoter and induced 
its expression in adult unc-73(ce362) mutants, after neuronal development is complete. A 50-min 
heat-shock induction of the transgene rescued the locomotion rate of unc-73(ce362) adults to greater 
than wild-type levels, whereas the same heat-shock treatment slowed the locomotion rate of control 
strains that lacked the transgene (Fig. 4A; Supplementary Movies). We conclude that the sluggish 
locomotion of unc-73 RhoGEF mutants is caused by functional, not developmental, defects.
Figure 4.
The slugg ishness of un c-73  RhoGEF m utants is cau sed  by defects in neuronal 
function, not neuronal developm ent. (A) UNC-73’s RhoGEF domain functions in 
adults, after neuronal developm ent is com plete. Locomotion ra tes  of control m utants 
com pared (more ...)
Animals can be sluggish due to a muscle problem or a nervous system problem. To determine the 
extent to which neuronal defects contribute to the sluggishness of unc-73 mutants, we transformed the 
unc-73(ce362) mutant with a transgene that expresses the unc-73e cDNA pan-neuronally. This 
transgene restored wild-type locomotion rates to the mutant (Fig. 4B). In summary, the results in 
Figure 4 show that the sluggishness of unc-73 RhoGEF mutants is caused by a defect in neuronal 
function, and not neuronal development or muscle function.
unc-73 RhoGEF mutants have drug sensitivities consistent with a mild deficit 
in ACh synaptic transmission
Given previous findings that egl-30 (Gaq) and goa-l (Gao) mutants exhibit pharmacological 
responses that are consistent with defective regulation of ACh synaptic transmission, we sought 
evidence that unc-73(ce362) mutants have decreased release of the neuromuscular neurotransmitter 
ACh. For this purpose, we used an assay that measures the time course of paralysis on the 
acetylcholinesterase inhibitor aldicarb. Since the secreted ACh that accumulates in the presence of 
aldicarb is toxic, mutations that decrease or increase the rate of ACh secretion confer resistance or 
hypersensitivity to aldicarb, respectively (Rand and Nonet 1997). The data showed that our strongest 
viable unc-73 mutant is only slightly resistant to aldicarb in this acute paralysis assay, and only at 
later time points in the assay (Fig. 5A). A transgene that expresses the unc-73e cDNA throughout the 
nervous system restores aldicarb sensitivity to wild-type levels in the unc-73(ce362) mutant 
background, which suggests that the mild aldicarb resistance at later time points is not due to 
irrelevant background mutations in the strain (Fig. 5A). In contrast, an egl-8 (PLCp)-null mutant 
assayed in parallel is resistant throughout the time course (Fig. 5A). These results argue for distinct 
functions of the UNC-73 RhoGEF domain and PLCp in driving locomotion, since their similar levels 
of sluggishness (as shown in the next section) are not reflected in similar aldicarb sensitivities.
Figure 5.
un c-73  RhoGEF m utants exhibit drug sensitivities consisten t with a mild deficit in 
ACh release . (A) un c-73 (ce362)  m utants exhibit delayed aldicarb-induced paralysis 
a t later time points relative to wild type and neuronally rescued  u n c-73(ce362). 
Shown (m ore ...)
For unknown reasons, some mutants that are defective in neurotransmitter release are hypersensitive 
to the nicotinic ACh receptor agonist levamisole (Nonet et al. 1993; Miller et al. 1996). Both egl-8 
(PLCp) mutants and our unc-73 RhoGEF mutants are significantly hypersensitive to the paralytic 
effects of levamisole, and this is rescued by the transgene that expresses the unc-73 cDNA 
pan-neuronally (Fig1_5B). Regardless of the explanation for the levamisole hypersensitivity, this 
suggests that the sluggishness and slight aldicarb resistance of unc-73 RhoGEF mutants are not 
caused by reduced response of the muscle to ACh. In summary, the results in Figure 5 are consistent 
with unc-73 RhoGEF mutants having only a mild deficit in ACh synaptic transmission; however, it is 
possible that up-regulation of the response to ACh, as reflected by the hypersensitivity, interferes with 
our ability to detect a strong ACh release defect by this method.
Double mutants disrupted for both PLC(5 and UNC-73 RhoGEF have synthetic 
phenotypes resembling Gaq nulls
We next investigated the relationship between UNC-73 (Trio) and the Gcto-Goq signaling network. 
Our finding that unc-73 RhoGEF mutants suppress mutants with an overactive Gaq pathway is 
consistent with UNC-73’s RhoGEF domain acting as an effector in the Gaq pathway, but it is also 
consistent with unc-73 mutations affecting Gaq pathway function indirectly. One way to test 
relationships within pathways is through double-mutant analysis. If UNC-73’s RhoGEF domain is the 
missing Gaq effector, then a double mutant lacking both PLC(3 and UNC-73 RhoGEF should have the 
phenotypes of a Gaq-null mutant. That is indeed what we found. Single mutants lacking only PLC(3 or 
only UNC-73’s RhoGEF domain were similarly sluggish, but not paralyzed; however, double mutants 
that were null for both proteins were almost completely paralyzed and had mean locomotion rates 
slightly lower than, but not significantly different from, a Gaq-null mutant (Fig. 6A; Supplementary 
Movies). Even the nonnull unc-73 RhoGEF mutants ce362 and ox317, when combined with PLC(3 
nulls, produced double mutants with locomotion rates close to a Gaq null (Fig. 6A). We also found 
that an unc-108 mutant (also isolated in thegoa-I suppressor screen) does not show a synthetic 
interaction with egl-8, even though it is more sluggish than the UNC-73 RhoGEF mutant (Fig. 6A). 
This latter result is consistent with our findings from the egl-8 enhancer screen (described above) 
showing that synthetic interactions with the egl-8 null are rare.
Figure 6.
Double m utants containing null or near-null m utations for both EGL-8 (PLCP) and 
UNC-73 RhoGEF domain phenocopy Gaq-null m utants. (A) eg l-8  (PLCP) and unc-73  
RhoGEF m utants show a  synthetic interaction for locomotion. The graph (more ...)
The unc-73 RhoGEF; egl-8 double mutants phenocopied egl-30 (Gaq)-null mutants in general 
appearance and growth characteristics as well as locomotion. For example, due to lack of locomotion, 
newly hatched egl-30 nulls and unc-73 RhoGEF; egl-8 double nulls (hereafter referred to as “double 
nulls”) remain folded as they were in the egg for hours after hatching (Fig. 6B; Supplementary 
Movies), egl-30 nulls and the double nulls also share an early larval growth arrest phenotype under
standard laboratory culture conditions (Table 1). Most arrested larvae remain alive for a week or 
more [75 ± 2.9% of unc-73(ev802); egl-8(sci47) double mutants were still alive after 10 d; n = 3 
populations of 20 animals each]. Much of the growth arrest phenotype of the double nulls is caused 
by absence of the UNC-73 RhoGEF, since the unc-73 RhoGEF-null mutant showed >50% larval 
growth arrest even as a single mutant, whereas the eg/-5-null mutants sa47 and mdl971 showed 0% 
and 18% larval growth arrest, respectively (Table 1). The unc- 73 RhoGEF-null mutants also took 
twice as long as the egl-8 nulls to grow from newly hatched larvae to adults (Table 1). A synthetic 
interaction for growth is also evident in nonnull allelic combinations of unc-73 RhoGEF; egl-8 
double mutants, which exhibit strongly reduced growth rates relative to each single mutant (Fig. 6C).
T able 1.
Larval arrest in unc-73\ egl-8 double m utants
A previous study found that the DAG analog phorbol myristate acetate (PMA), if mixed in the right 
dosage into the media of culture plates, could restore wild-type levels of locomotion to Gciq-null 
mutants within 2 h (Reynolds et al. 2005). If the double null mutants are essentially the same as 
Gctq-null mutants, then we should also be able to rescue their paralysis with PMA, and that is indeed 
the case. Within 2 h of transferring the double null mutants to a plate containing 2.5 (iM PMA, their 
locomotion rate improved ~3 60-fold, to a level greater than that of wild-type animals on control 
plates containing carrier only (Fig. 6D; Supplementary Movies). It is not clear whether the rescuing 
effects of PMA are due solely to overactivation of the PLCp effector branch, thus compensating for 
lack of a Trio RhoGEF effector branch, or whether the Trio RhoGEF effector branch ultimately 
regulates DAG levels as well.
The synthetic interaction of PLCp and UNC-73 RhoGEF nulls involved the egg-laying behavior as 
well as growth and locomotion. In C. elegans, the egg-laying rate can be quantified independent of 
growth rate by assessing the developmental stages of the eggs that are laid (Jose et al. 2007). Animals 
with high egg-laying rates lay early-stage eggs with eight or fewer cells rather than retaining the eggs 
in the uterus until the ~50- to 100-cell stage as wild type does (Jose and Koelle 2005). Animals with 
low egg-laying rates lay eggs in which embryos have developed to later stages, such as the comma, 
twofold, or threefold stages. Extremely low egg-laying rates result in internal hatching and a 
“bag-of-worms” phenotype caused by the hatchlings consuming the parent. We found that an egl-8 
(PLCp) null showed a reduced egg-laying rate, but it was not nearly as severe as an egl-30 (Gaq) 
strong reduction-of-function mutant. Specifically, egl-8(mdl971) laid 5% of its eggs at the two- or 
threefold stage compared with 50% for egl-30(ad805). Furthermore, 0% of egl-8 nulls had died of 
bag-of-worms within 48 h of reaching adulthood compared with 41% for egl-30(ad805) (Table 2). 
These result confirm that there is a missing Gaq effector for egg laying, as others had inferred 
(Bastiani et al. 2003). Our data show that Trio’s RhoGEF domain plays a more critical role in egg 
laying than PLC(3, since 93% of the eggs laid by the ev802 UNC-73 RhoGEF-null mutant are laid at 
the two- or threefold stage (Table 2). UNC-73 RhoGEF appears to be involved in Gaq signaling 
during egg laying because unc-73 RhoGEF mutations strongly suppress the hyperactive egg laying of 
mutants with an overactive Gaq pathway (Table 2). We therefore quantified the egg-laying rate of 
unc-73; egl-8 doubles to test for a synthetic interaction. Since the double null is larval arrested and 
thus cannot produce eggs, we assayed the nonnull unc-73(ce362) mutation in combination with an 
egl-8 null. This double mutant showed a synthetic effect on egg laying. Whereas eg/-5-null and 
unc-73(ce362) single mutants laid 5% and 62% of their eggs at the two- or threefold stage, 
respectively, the double mutant laid 98% of its eggs at these late stages (Table 2). In addition, 100% 
of the double mutants died of bag-of-worms within 48 h of reaching adulthood, whereas 0% and 8% 
of the eg/-5-null and unc-73(ce362) single mutants, respectively, died of internal hatching (Table 2). 
A previous study found that mutations affecting UNC-73’s Rac-specific GEF domain cause the
bag-of-worms phenotype due to defective migration of the vulval precursor cells (Spencer et al. 
2001). However, the bag-of-worms phenotype that we observed results from functional, not 
developmental, defects because phorbol esters restored egg laying in the double mutant to 
approximately wild-type levels within 2.5 h (Table 2).
Table 2.
UNC-73 RhoGEF and PLC|3 pathw ays interact to drive egg laying
In summary, the results in Figure 6 and Table 2 are consistent with PLCp and Trio’s Rho-specific 
GEF domain acting in separate pathways that together mediate the Gaq signaling that drives the 
locomotion, growth, and egg laying of the animal. Our data show that the Trio RhoGEF pathway is 
the dominant pathway for driving growth and egg laying, whereas the two pathways make about equal 
contributions in driving the locomotion behavior.
UNC-73E binds in a stable complex with activated EGL-30 (Gaq)
If, as the above results suggest, UNC-73’s RhoGEF domain is part of a Gaq effector pathway, Gaq 
might physically interact with the RhoGEF domain to cause RhoA activation, just as Gaq physically 
interacts with PLCp to activate its phospholipase activity. Alternatively, Gciq’s activation of RhoA 
could be indirect; i.e., mediated by Gaq signaling through one or more upstream proteins. However, 
our results argue against the latter possibility because we found that activated Gaq can physically 
associate with a stable complex containing UNC-73E when activated EGL-30 (Gciq) and Flag-tagged 
UNC-73E are expressed together in human embryonic kidney (HEK293) cells, as determined by 
coimmunoprecipitation experiments (Fig. 7). This suggests that, in a cellular environment, activated 
C. elegans Gaq and UNC-73E (Trio RhoGEF) have a close physical interaction that mirrors their 
close genetic interaction in living animals.
Figure 7.
Activated EGL-30 (G aq) coim m unoprecipitates in a  stab le  com plex with UNC-73E 
(Trio RhoGEF) when coexpressed  in HEK293 cells. HEK293 cells w ere transfected 
with 1 |jg of un c-73E  cDNA, 1 |jg of activated eg l-3 0  (G aq Q205L), (more ...)U,c, '
Human Trio and UNC-73E enhance the activation of RhoA by EGL-30 (Gaq)
To test whether Trio, and specifically the Rho-specific GEF domain of Trio, can mediate activation 
of RhoA by Gaq, we transfected various combinations of activated Ga and Trio cDNAs into HEK293 
cells and assayed for RhoA activation using two different assays. In the first assay, we monitored 
RhoA activation in intact cells using a reporter that produces luciferase in response to Rho-dependent 
transcription driven by the serum response element (SRE) promoter coupled to a luciferase cDNA 
(Mao et al. 1998; Lutz et al. 2004). In different experiments, we transfected four Trio constructs into 
the cells: (1) a full-length version of human Trio; (2) a fragment of human Trio consisting mainly of 
the Rho-specific GEF domain (Trio RhoGEF); (3) a full-length unc-73e cDNA; and (4) a fragment of 
unc-73e consisting mainly of the Rho-specific GEF domain (UNC-73E RhoGEF) (Fig. 8A). In cells 
lacking exogenous Gaq cDNA, the longer Trio constructs stimulated a weak basal level of luciferase 
production, which suggests that Trio is a very inefficient RhoGEF in the absence of an activator 
protein (Fig. 8B). The shorter constructs exhibited an even lower basal GEF activity (Fig. 8B). Cells 
transfected with constitutively active EGL-30 (Gaq) Q205L showed a basal stimulation of RhoA
activity due to the presence of an endogenous Trio-like protein that the cells express (Lutz et al.
2005). Upon coexpression with the various Trio proteins, the luciferase production induced by 
activated EGL-30 (Gaq) was enhanced in a synergistic manner (Fig. 8B). Although the unc-73e 
construct had the strongest effect in this assay (~3.3-fold enhancement), full-length human Trio and 
the shorter RhoGEF domain constructs also caused synergistic luciferase production (approximately 
twofold enhancement) (Fig. 8B), which suggests that all of the Trio constructs enhance RhoA 
activation by activated EGL-30 (Gaq). Because we isolated two of our unc-73 suppressor mutants as 
suppressors of a Ga<)-null mutant, we also performed the same set of transfections with activated 
GOA-1 (Gao) substituted for activated EGL-30 (Gaq)..Compared with the vector control, activated 
GOA-1 (Ga0) did not induce luciferase production and also did not show the large cooperative 
enhancement elicited by coexpression of activated EGL-30 (Gaq) and the Trio variants (Fig. 8B).
As a direct assay for RhoA activation, we assayed the amount of GTP-liganded RhoA induced by the 
various cDNAs using the RhoA-binding domain of rhotekin fused to GST to pull down activated 
RhoA-GTP (Ren and Schwartz 2000; Lutz et al. 2004). In this assay, expression of UNC-73E,
EGL-30 (Gaq) Q205L, and GOA-1 (Ga0) Q205L alone caused only marginal increases in the level of 
RhoA-GTP, whereas coexpression of UNC-73E and EGL-30 (Gaq) Q205L, but not coexpression of 
UNC-73E and GOA-1 (Ga0) Q205L, resulted in strong activation of RhoA (Fig. 8C). Taken together, 
all of these results suggest that activated EGL-30 (Gaq) can induce RhoA activation via stimulation of 
UNC-73E (Trio RhoGEF).
An unc-73 RhoGEF mutation impairs Gaq-stimulated RhoA activation
The above data predict that the missense mutations recovered in our genetic screens should prevent or 
reduce Gaq-stimulated RhoA activation. To test this, we first analyzed the effect of the unc-73(ce362) 
mutation, which is the strongest missense mutation, on RhoA activation in intact cells using the 
luciferase reporter system described above. Although the mutant UNC-73E was expressed at levels 
similar to wild-type UNC-73E, the mutant protein was nearly inactive in Gaq-stimulated RhoA 
activation, since the level of luciferase production was similar to cells containing Gaq without 
exogenous UNC-73 RhoGEF (Fig. 9A).
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Figure 8.
Activated EGL-30 (G aq), but not activated GOA-1 (G a0), synergizes with Trio and 
UNC-73E to activate RhoA in HEK293 cells. (A) Shown a re  the domain 
arrangem ents of the full-length and truncated  Trio and un c-73  cDNAs used  for the 
cell transfection (m ore ...)
Figure 9.
An UNC-73 RhoGEF mutation strongly impairs G aq-stim ulated RhoA activation in 
cells and purified proteins. (A) The u n c-7 3 (ce3 6 2 )  mutation severely impairs 
Gaq-stim ulated Rho'A activation in intact cells. The ability of C. e le g a n s  G a (more ...)
To gain molecular-level insights into the functions disrupted by the ce362 mutation, we mapped the 
mutation onto the structure of the vertebrate Gaq-p63RhoGEF- RhoA complex (Lutz et al. 2007) and 
then produced purified p63RhoGEF harboring the mutation to analyze its effects on the molecular 
activities of the complex. The residue mutated in unc-73(ce362) is conserved in human Trio and its 
paralogs, Kalirin/Duet and p63RhoGEF. The mutation is an Ile-to-Asn change of a solvent-exposed 
residue of the DH domain, on the surface opposite to the RhoA interaction site. In the structure, this 
isoleucine contributes to the interface with the C-terminal helix of Gctq, and its substitution may also 
perturb local secondary structure in the region, which may also serve to lower affinity for the Ga 
subunit. Using purified proteins, we found that the ce362 mutation decreases the basal RhoA 
nucleotide exchange activity [400 nM wild type activates nucleotide exchange on RhoA by 1.4 ±
0.1-fold (n = 12); 400 nM mutant activates by 1.1 ± 0.1-fold (n = 5)], lowers the affinity of Gctq 
binding by threefold (Fig. 9B), and also strongly impairs Gaq-stimulated RhoA activation (Fig. 9C). 
When taken together with the cell-based RhoA activation data, these results are consistent with the 
ce362 mutation strongly impairing the ability of Gctq to activate RhoA through Trio’s Rho-specific 
GEF domain.
D iscu ss io n
In this study, we used two forward genetic screens to query the C. elegans genome for proteins 
important for Gaq signaling. By screening for mutants that suppress the phenotypes of an overactive 
Gaq pathway, both screens yielded mutations that specifically disrupt the RhoGEF domain of 
UNC-73 (Trio). Although the Rac-specific GEF domain in the longer isoforms of UNC-73 plays a 
prominent role in neuronal development (Steven et al. 1998), we used inducible and cell-specific 
promoters, as well as phorbol ester rescue experiments, to show that the Rho-specific GEF domain 
functions in adult neurons, after neuronal development is complete. In complementary genetic, 
biochemical, and cell-based experiments, we showed that Trio’s Rho-specific GEF domain is a major 
Gaq effector that, together with PLCp, mediates the Gctq signaling that drives the locomotion, egg 
laying, and growth of the animal. These results add important insights to an emerging body of 
evidence linking Gctq-coupled receptors or activated Gaq to RhoA signaling. Specifically, they 
identify the primordial Gctq effector whose duplication and divergence led to the Trio RhoGEF family 
of Gctq effectors, and they show that the Trio RhoGEF effector pathway can be as important as, or 
even more important than (for example, in driving growth and egg laying in C. elegans), the 
canonical PLCp effector pathway in mediating Gotq signaling in living animals.
Genetic, biochemical, and structural approaches converge to identify Trio’s 
Rho-specific GEF domain as a major, evolutionarily conserved Gaq effector
Interestingly, the ability of the Rho-specific GEF domain of Trio to function independently as a Gctq 
effector has been evolutionarily conserved. Like C. elegans, humans make splice variants of Trio that
lack the Rac-specific GEF domain but contain the RhoGEF domain (Portales-Casamar et al. 2006). In 
addition, two paralogs, Kalirin/Duet and p63RhoGEF, are found in the human genome (Souchet et al. 
2002; Lutz et al. 2004), of which Duet and p63RhoGEF exclusively contain the Rho-specific GEF 
domain. Of these, p63RhoGEF was the .first RhoGEF shown to be physically and specifically coupled 
to activation by Gaq (Lutz et al. 2005). However, these observations have now been extended to the 
RhoGEF domains of human Trio and Kalirinin/Duet (Lutz et al. 2007; Rojas et al. 2007). These 
studies used purified proteins to show that activated Gaq directly interacts with the RhoGEF at 
specific sites, and that activated Gotq and the RhoGEF domain are sufficient to drive RhoA nucleotide 
exchange (Lutz et al. 2007; Rojas et al. 2007). The recently solved crystal structure of the -
Gaq-p63RhoGEF-RhoA complex revealed that Gotq interacts with the DH/PH motifs of the GEF 
domain in a manner expected to relieve autoinhibition of the catalytic DH domain by the accessory 
PH domain, with the C-terminal tail of the PH domain docking into the Gotq effector-binding site and 
the C-terminal region of Gaq binding the DH domain (Lutz et al. 2007). Unlike vertebrates, C. 
elegans has only one Trio ortholog (UNC-73) and produces domain diversity in Trio proteins by 
alternative promoters and splicing. Thus the primordial Gotq effector was most likely a Trio ortholog 
that underwent duplication to produce the paralogs p63RhoGEF and Kalirin/Duet, which may allow 
for specialized Gotq effector functions and/or sites of expression in vertebrates. This interpretation of 
conserved Gaq effector function is further supported by the finding that the unc-73(ce362) and 
unc-73(ox322) mutations map either directly in or are predicted to be disruptive of the p63RhoGEF 
DH and PH domain interfaces with Gotq (Lutz et al. 2007), and, as shown in this study, the ce362 
mutation disrupts the ability of Gotq to activate p63RhoGEF. Thus, complementary approaches 
ranging from the genetics of living animals down to the structure of molecular complexes have 
converged on an important conclusion: The Rho-specific GEF domain that is found in the Trio family 
of proteins is a major, evolutionarily conserved, direct effector of Gaq.
The PLCp and RhoA effector pathways are both important for Gaq signaling 
in living animals
Can the two Gaq effector pathways act in the same cells, or do some cell types predominantly use one 
of the pathways? Evidence from previous C. elegans studies suggests that both scenarios exist. For 
example, both egl-30 (Gaq) and some unc-73 RhoGEF-containing isoforms are expressed in the 
vulval muscles that mediate egg laying and in the pharynx (Bastiani et al. 2003; Steven et al. 2005). 
UNC-73 RhoGEF has also been shown to function in the pharynx (Steven et al. 2005). In contrast, 
egl-8 (PLCP) seems to be absent or below detection limits in the vulval muscles and pharynx 
(Lackner et al. 1999; Miller et al. 1999). However, there do not seem to be any tissues that express 
both egl-30 (Gaq) and egl-8 (PLCP) but not unc-73 (Trio RhoGEF), and all three proteins are 
strongly expressed together throughout the nervous system (Lackner el al. 1999; Miller et al. 1999; 
Bastiani et al. 2003; Steven et al. 2005). egl-8 is also expressed without unc-73 (Trio RhoGEF) or 
egl-30 (Gaq) in the posterior intestine, where it regulates a Gaq-independent posterior body wall 
muscle contraction during defecation (Lackner et al. 1999; Miller et al. 1999). The close 
correspondence between Gaq and Trio RhoGEF expression in various tissues, the apparent lack of 
PLCp expression in some Gaq-expressing cells, and our finding that the Trio RhoGEF pathway is the 
dominant pathway for driving growth and egg laying raise the interesting possibility that Trio’s 
Rho-specific GEF domain may be the primordial Gotq effector, and that PLCp may have been coopted 
as an additional Gaq effector for specific cell types at a later point in evolution. However, the recently 
completed draft sequence of the Nematostella sea anemone genome (Putnam et al. 2007) revealed 
orthologs (defined as reciprocal best-scoring BLAST hits) of all three proteins (Gaq, PLCp, and Trio) 
(data not shown). Thus Gaq, orthologs of which are not found outside the animal kingdom, may 
already have been signaling through both PLCp and Trio in the last common cnidarian-bilaterian 
animal ancestor, which lived an estimated 670-820 million years ago (Putnam et al. 2007). Although 
this underscores the ancient origin of the pathway, further clues of its evolutionary history will have 
to await the forthcoming genomes of even simpler animals and animal precursors, such as sponges, 
placozoans, and choanoflagellates.
In C. elegans, both EGL-8 (PLC|3) and LTNC-73 RhoGEF function in the nervous system to drive the 
locomotion behavior, and knocking out either effector results in similarly sluggish locomotion. Thus, 
both effector pathways make similarly important contributions to locomotion. Given that Gaq and 
both of its effectors are broadly expressed in the nervous system, we speculate that, in many neurons, 
Gctq may activate both pathways in the same cell. Previous studies provided evidence that EGL-30 
(Gaq), EGL-8 (PLCP), and RHO-1 (RhoA) control locomotion and neurotransmitter release by acting 
in the cholinergic motor neurons that are the final link between synaptic transmission and the 
locomotion behavior (Lackner et al. 1999; McMullan et al. 2006). These findings, coupled with the 
finding that some of the UNC-73 RhoGEF isoforms (such as LTNC-73E) are strongly expressed in 
both head and motor neurons (Steven et al. 2005), suggest that both effector pathways can function in 
the same neurons. However, we have been unable to directly demonstrate that UNC-73 RhoGEF 
functions in motor neurons. Indeed, expression of UNC-73E under control of a motor neuron 
promoter had no effect on the sluggish locomotion phenotype of unc-73(ce362) (data not shown), 
whereas expression under a pan-neuronal promoter gave full rescue (i.e., Fig. 4B). This suggests that 
UNC-73 RhoGEF is required in other neurons as well as motor neurons or, less likely, that it is only 
required in nonmotor neurons.
Other sources of RhoA activation in regulating synaptic signaling
Biochemical and structural studies in vertebrates have clearly shown that Gaj2/Gan functions as a 
major activator of RhoA through its direct interactions with the RGS domain of pi 15RhoGEF (Hart 
et al. 1998; Katoh e( al. 1998; Wells et al. 2002). Previous C. elegans studies also identified GPA-12 
(Gci|2) as an activator of pi 15 RhoGEF and RHO-1 (RhoA) (Yau et al. 2003; Hiley et al. 2006). 
Hyperactivating this pathway, which is broadly expressed in C. elegans neurons, increases aldicarb 
sensitivity and causes exaggerated body movements through its effects on inhibiting DGK-1 
(diacylglycerol kinase), to which RHO-1 directly binds (Hiley et al. 2006; McMullan et al. 2006). 
However, deletions of GPA-12 or pi 15 RhoGEF have no obvious effect on locomotion rate or 
aldicarb sensitivity (Hiley et al. 2006), which indicates that one or more other RhoA activators 
contribute to the sluggish phenotype and aldicarb resistance of animals expressing the Rho inactivator 
C3 transferase (Hiley et al. 2006; McMullan et al. 2006). The sluggish phenotype of animals lacking 
UNC-73 RhoGEF is consistent with UNC-73-activated RHO-1 being a major target in C3 
transferase-induced sluggishness. However, the relatively mild aldicarb sensitivity of unc-73 RhoGEF 
mutants (this study) compared with animals expressing C3 transferase (McMullan et al. 2006) 
suggests that other RhoA activation pathways may contribute to synaptic signaling in C. elegans.
M ate ria ls  and  m ethod s
Forward genetic screens
For the egl-8(mdl971) enhancer screen, we EMS-mutagenized egl-8(mdl971); ceExl49 (rab-3m. '■ 
egl-8 cDNA/rab-3: :GFP) L4-stage animals and produced synchronous F2 adult grandprogeny of the 
mutagenized animals. We then plated a single animal carrying the GFP-marked array on each of 2000 
solid-media culture wells on 24-well plates and incubated the plates for 4 d at room temperature to 
produce the F3 generation. The ceExl49 extrachromosomal array rescued the sluggish locomotion of 
eg/-S-null mutants and transmitted the array to -60% of its progeny. We therefore screened the plates 
for wells in which all of the animals that had lost the rescuing array were arrested as <?g/-50-null-like 
paralyzed larvae, or for wells in which the array-less animals appeared synthetically paralyzed 
relative to their array-containing siblings in the well. We repeated the screen for 13 weekly cycles for 
a total of 26,000 F2s plated, which is approximately threefold knockout coverage for the genome. For 
the goa-l(sa734) suppressor screen, we mutagenized L4-stage goa-1 mutants with 1 mM ENU 
dissolved in ethanol (De Stasio and Dorman 2001). goa-1 (sa734) is a null mutant with an early stop 
codon (Robatzek and Thomas 2000). We produced synchronous F2 grandprogeny of the mutagenized
animals and plated these animals as young larvae on 24-well culture plates using a repeat pipetter to 
plate -100 animals in each well for a total of 50,000 animals. We screened both the F2 and F3 
generations on these plates, but had the most success in screening the F3 generation, which involved 
growing the cultures for 2 d at room temperature and 4 d at 20°C after plating. We screened the wells 
for mutants with improved growth and reduced hyperactive behaviors, including both locomotion and 
egg laying. We identified the unc-73(ce367) goa-l(sa734) double mutant on our goa-l(sa734) stock 
plates as a spontaneous suppressor with a strong growth advantage over goa-l(sci734) single mutants. 
For the egl-30(tg26) suppressor screen, we mutagenized young adult egl-30(tg26) animals with 0.5 
mM ENU and picked them in groups of five to 20 animals to 6-cm agar plates. The FI progeny were 
washed off after laying eggs, and the semisynchronous F2 broods were screened for improved growth 
and reduced hyperactivity. Approximately 18,000 haploid mutagenized genomes were screened. 
egl-30(tg26) contained the R243Q mutation that decreases GTP hydrolysis and results in a dominant 
hyperactive locomotion and slow-growth phenotype (Doi and Iwasaki 2002; Natochin and Artemyev 
2003; Reynolds et al. 2005).
Mapping, identification, and outcrossing of suppressor mutations
Before mapping the new suppressor mutations, we separated the mutations fromgoa-1 (sa734) or 
egl-30(tg26) by crossing N2 males to the suppressed strain and isolating putative suppressor single 
mutants in the F2 generation based on their predicted sluggish phenotype. Animals that were both 
homozygous for the mutation and did not segregate goa-1 (sa734) or egl-30(tg26) were kept as 1* 
outcrossed strain stocks. In the case of the unc-73(ce362) allele, we produced an unc-73(ce362); 
dpy-1 l(e224) double mutant for use in complementation tests and a 3X outcrossed version of the 
mutant that we then used to make the final 5X outcrossed versions of unc-73(ce362) and 
unc-73(ce362) goa-l(sa734). In the course of outcrossing ce362, we found tight linkage to goa-1 on 
Chromosome I. We then mapped the mutation relative to single-nucleotide polymorphisms (SNPs) 
using methods similar to those described previously (Schade et al. 2005) to further narrow the 
location to a region centered around -1.8 on Chromosome I that included the unc-73 gene. 
Complementation tests revealed that the sluggish phenotype of unc-73(ce362) partially 
noncomplemented unc-73(e936), whereas ce362 and ce367 fully noncomplemented each other and 
unc-73(ev802). PCR and sequencing of the unc-73 gene in our mutants revealed mutations in the 
Rho-specific GEF domain. ox317 and ox322 failed to complement each other and were mapped with 
SNPs (Davis et al. 2005) to an interval on Chromosome I slightly left of cosmid E01A2 (-1.66) and 
very close to cosmid F28H1 (-1.87). Fine mapping was aided by picking Dpy non-Unc and Unc 
non-Dpy recombinants from ox317 dpy-5(e61)/CB4856. ox317-complemented unc-73(e936), but 
failed to complement unc-73(ev802), and sequencing confirmed that ox317 and ox322 carried 
mutations in the Rho-GEF domain of unc-73.
Live animal assays
For larval arrest assays, we picked gravid adults to culture plates and allowed them to lay eggs for 16 
h. We then transferred 20 of the youngest larvae from the hatched eggs on the plate to each of three 
locomotion plates and monitored them twice a day over the next 10 d, picking off any animals that 
had matured to adults, eggs that had been laid, or larvae that had died during each 12-h period. 
Larvae that died by desiccation after crawling off of the media or unaccounted/missing larvae were 
not included in the final numbers. We used these same plates to quantify the number of 
unc-73(ev802); egl-8(mdl971) double mutants that remained alive after 10 d. Death was defined as 
absence of stimulated movement in the tip of the nose when prodded with a platinum pick, 
accompanied by the appearance of partial decomposition. For growth rate assays, we plated a 
predetermined number of LI larvae on each of three growth assay plates (see “Worm Strains and 
Culture” in the Supplemental Material) and incubated them for 96 h at 20°C. The number of LI 
larvae per plate was strain-specific and based on estimates of the growth rate and the number needed 
to produce ~300-500 progeny over the 96 h. For strains with wild-type growth, we plated four LI
larvae per plate. We then counted the FI progeny (eggs and larvae) and normalized the data to 
progeny per animal plated. We performed standard locomotion assays as described (Miller et al.
1999; Reynolds et al. 2005). For strains with 100% larval arrest [egl-30(ad810) and doubles with 
unc-73(ev802)], we collected 6- to 30-h-old larval-arrested animals as progeny of balanced 
heterozygotes (see the Strain list in the Supplemental Material) and identical stage controls of N2 
(wild type) as described for other larval-arrested strains (Reynolds et al. 2005). For all locomotion 
assays using larvae, we counted body bends for a single 6-min period for each of 10-15 animals that 
had been freshly plated on standard locomotion plates and stabilized 2-4 h before assaying. We 
performed locomotion assays of phorbol ester-treated animals as described (Reynolds et al. 2005), 
using 5 [iM PMA and a 2.5-h time point for unc-73(ce362); egl-8(mdl971) adults and 2.5 |iM PMA 
with the following time points for assays using larvae: 1.0 h (N2), 1.5 h [unc-73(ev802)], 2 h 
\unc-73(ev802); egl-8(mdl971)]. We performed heat-shock locomotion assays as described (Schade 
et al. 2005). For egg-laying assays, we aged animals 15 h from the mid-L4 or young adult stage (the 
latter if the strain was very slow growing), and then distributed equal numbers (the exact number 
plated was strain-specific) to each of three spot plates (made by spotting 6 [iL of OP-50 bacteria to an 
unseeded plate and growing for 24 h at room temperature). We then scanned the spot of bacteria 
hourly [or every 30 min for wild type, PMA-treated strains, and goa-l(sa734')] for up to 9 h or until 
-300 eggs (100 per trial plate) had been laid in the bacteria and counted. After noting the 
developmental stage of each egg laid during the preceding time interval, we picked all eggs off of the 
bacteria. We preincubated PMA-treated strains on 5 [iM PMA assay plates for 4-5 h, and then picked 
off the eggs that had been laid during the preincubation before beginning the first 30-min interval.
This allowed sufficient time for the PMA to induce laying of the late-stage eggs that were in the 
uterus before PMA exposure and that would otherwise bias the early time points of the assay. We 
used a 2.5X objective (225x magnification) to assess the stage of each egg, and a 1.2X objective with 
a longer working distance to pick off eggs after each time point. After the assay, we saved the plates 
and noted the number of animals that died over the next 48 h due to internal hatching. We performed 
aldicarb and levamisole paralysis assays as described (Charlie et al. 2006b). We captured and 
converted videos of worms on culture plates as described (Schade et al. 2005).
Double mutants
We constructed double mutants using the standard method of crossing heterozygous males of mutant 
A with homozygous hermaphrodites of mutant B and cloning virgin FI cross-progeny. From plates 
segregating mutant A in their F2 progeny, we cloned mutant A or B animals and looked for 
segregation of the double mutant in the next generation. To facilitate identification of some unc-73; 
egl-8 and unc-108; egl-8 double mutant combinations, we marked egl-8 mutants with the dpy-5(e6l) 
mutation such that the crosses placed the dpy-5 mutation in trans to the closely linked unc-73 or 
unc-108. This allowed us to identify animals homozygous for the desired chromosome, or to identify 
balanced unc-73(ev802) heterozygotes for making unc-73(ev802); egl-8 loss-of-fimction doubles.
The homozygosity of the unc-73(ce362); egl-8(mdl971) double mutant was verified by PCR and 
sequencing. We made unc-73(ev802); egl-8(mdl971); qals7312 using similar methods, except that 
we used a pan-neuronal GFP marker in qals7312 to follow the array.
Cell culture and transfection
Human embryonic kidney cells (HEK293) were maintained in high-glucose Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% heat-inactivated fetal calf serum, 100 U/mL 
penicillin, 100 [ig/mL streptomycin, and 2 mM glutamine at 37°C in an atmosphere of 5% CO2. DNA 
transfections were performed with Polyfect (Qiagen) according to the manufacturer’s 
recommendations in 96-well and six-well formats for measuring SRE activation and RhoA activation 
or protein interaction, respectively. After transfection, the cells were maintained in serum-reduced 
(0.5%) DMEM for 48 h.
Rho activity assays
To quantify Rho-dependent SRE activation, reporter gene assays were performed with the Dual 
Luciferase Reporter Assay System (Promega) according to the manufacturer’s protocol as described 
previously (Mao et al. 1998; Lutz et al. 2004). In brief, HEK293 cells were seeded into 96-well plates 
and cotransfected with the indicated plasmids (30 ng of C. elegans Ga plasmids, 60 ng of the 
respective unc-73/Trio plasmids, and up to 90 ng of an empty control vector as indicated) together 
with the pSRE.L firefly luciferase reporter plasmid (21 ng; kindly provided by Dr J. Mao and Dr. D. 
Wu, University of Rochester, NY) and the pRL-TK (4 ng; Promega) Renilla luciferase control vector. 
Forty-eight hours after transfection, the cells were lysed with passive lysis buffer (Promega), and 
luciferase activities were determined with the Envision Instrument (Perkin Elmer) in a white 96-well 
plate. We also determined RhoA activation by a Rho effector pull-down assay as described 
previously (Ren and Schwartz 2000; Lutz et al. 2004). In brief, HEK293 cells were seeded in six-well 
plates and transfected with the respective plasmids (1.3 |ig unc-73e plasmid in the absence or 
presence of 0.6 |ig of the respective Ga plasmids and up to 2 |ig of an empty control vector). 
Forty-eight hours after transfection, the cells were scraped off in a buffer containing 1% (v/v) Nonidet 
P40. The precleared lysates were incubated for 1 h on ice with 70 ug of purified GST-Rho-binding 
domain of Rhotekin bound to glutathione-Sepharose while continuously shaking. After three washing 
steps, the bound proteins were eluted with sample buffer and separated by 15% SDS-PAGE. RhoA 
was then detected by immunoblotting with a specific RhoA antibody (1 ug/mL; 26C4; Santa Cruz 
Biotechnology). The expression level of the proteins and exogenous RhoA was analyzed in 40 (j.g of 
the precleared lysates.
Immunoprecipitations
For coimmunoprecipitation of UNC-73E with different constitutively active Ga subunits, HEK293 
cells were seeded in six-well plates and transfected with the respective plasmids and up to 2 |ig of an 
empty control vector. Forty-eight hours after transfection, the cells were lysed with 600 |iL of 
immunoprecipitation buffer (10 mM Tris-HCl at pH 7.4, 150 mM NaCl, 0.1% Triton X-100, protease 
inhibitor tablets [Roche]) and homogenized for 30 sec. After centrifugation (26,000g for 10 min at 
4°C), the supematants were precleared with 40 (J.L of a 1:1 slurry of protein A Sepharose (GE 
Healthcare). Then, 2 ng of anti-Flag M2 antibody (Sigma-Aldrich) were added to each sample and 
incubated for 30 min on ice. After addition of 40 uL of equilibrated protein A Sepharose, the samples 
were gently shaken for 4 h at 4°C. After three washing steps, the bound proteins were eluted and 
denaturated with 25 ul. of sample buffer for 5 min at 95°C. The precipitated proteins were analyzed 
by separating 10—40 |ig of protein by discontinuous SDS-PAGE (10%—15% acrylamide) and 
transferring onto a nitrocellulose membrane. For detection of specific proteins, the following 
antibodies were used: anti-Flag-M2 antibody (1.0 |ig/mL; Sigma-Aldrich) for detection of 
N-terminally Flag-tagged Trio, anti-RhoA antibody (1 ug/mL; 26C4; Santa Cruz Biotechnology), 
anti-Gaq/n antibody (0.2 ug/mL; C-19; Santa Cruz Biotechnology), and anti-GOA-1 antibody (gift of 
Michael Koelle, Yale University, New Haven, CT).
Biochemical analysis of the ce362 mutation
With the exception of the Gal q chimera, we expressed all of the proteins for this analysis in bacteria 
and purified them as described (Lutz et al. 2007). These included wild-type and mutant versions of 
p63RhoGEF (p63RhoGEF and p63RhoGEF-I205N, the latter of which contains the ce362 mutation) 
and RhoA. We purified Gaj/q chimeras from insect cells as described (Tcsmer et al. 2005). For the 
Gaq-binding competition experiment, we mixed increasing concentrations of unlabeled wild-type 
p63RhoGEF (residues 149-502) and its I205N mutant with 100 nM p63RhoGEF labeled with 
Alexa-Fluor 532, and then incubated with Gaj/q-linked .vMap LumAvidin microspheres (Luminex) in 
20 mM HEPES (pH 8.0), 100 mM NaCl, 5 mM MgCl2, 0.1% lubrol, 5 mM DTT, 1% BSA, 20 
AICI3, and 10 mM NaF. The bead-associated fluorescence was measured in a Luminex 96-well plate
bead analyzer, in duplicate. Data were fit to a single site competition curve using GraphPad Prism. 
The Kd of fluor-labeled p63RhoGEF-I205N for Gccj/q is 96 ± 27 nM (n = 3), which is not 
significantly different from the K& of the unlabeled mutant protein in Figure 9. We measured RhoA 
exchange activity by fluorescence polarization as described in a companion publication (Lutz et al.
2007). A one-phase exponential association curve with time lag was used to fit each curve, generated 
by mixing 2 |iM RhoA with either 200 nM wild-type p63RhoGEF (residues 149-502) or the I205N 
mutant, and with increasing amounts of Gccj/q, as indicated. In each individual experiment, curves 
were measured in triplicate, and their kapp values were fit simultaneously to single-phase exponential 
association curves in GraphPad Prism. The rate versus Goy/q concentration was then fit to a saturation 
binding with ligand depletion curve (rate = (Bmax/[GEF]) * ((Kd + [GEF] + [Ga;/q]) -  ^(Kd + [GEF] 
+[Gai/q])2-  (4 * [GEF] * [G<Xi/q]))/2).
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